MTMaria de Toledo

Maria de Toledo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria de Toledo has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epileptic and developmental encephalopathy secondary to inversion‐duplication of chromosome 15: Description of epilepsy characteristics and therapeutic outcomes

    by Cristina Benítez‐Provedo, Marta García‐Fernández, Eva Gutiérrez‐Delicado, Elena González‐Alguacil, Nelmar Valentina Ortiz‐Cabrera, Bárbara Fernández‐Garoz, Juan José García Peñas, Nuria Lamagrande Casanova, María Ballarà‐Petitbò, Anna Duat Rodríguez, et al.

    Objective: Inversion‐duplication syndrome of chromosome 15 (invdup15) is a chromosomal disorder characterized by an inverted duplication of 15q11.2‐q13.1. Epilepsy is highly prevalent (60%–80%), drug‐resistant, and may progress to developmental epileptic encephalopathies (DEEs) such as Lennox–Gastaut syndrome (LGS). Despite its impact, epilepsy and optimal treatments remain poorly described. Methods: A retrospective multicenter study across 37 Spanish hospitals analyzed 54 patients, divided into two genetic subgroups: invdup15q and intdup15q. Clinical and genetic data were reviewed, focusing on epilepsy onset, seizure types, syndrome progression, electroencephalographic (EEG) findings, and treatment response. Results: Epilepsy was present in 29 of 54 (54%) patients, with a mean age at onset of 7.4 years (range = 1 month–24 years, SD = 6.4). LGS (16/29, 55%) and focal epilepsy (15/29, 52%) were the most frequent epilepsy types, although infantile epileptic spasms predominated in younger patients (5/6, 83%). Late onset LGS (>8 years) occurred in 38%. Initial seizures were mostly focal motor (10/29, 34%) and generalized tonic–clonic seizures (8/29, 28%), later evolving to tonic, myoclonic, and atypical absence seizures. Twenty‐six of 29 (90%) reported drug‐resistant epilepsy. Epilepsy was more frequent (65% vs. 35%, p < .05) and had earlier onset (median = 5.7 vs. 12.3 years) in invdup15q than intdup15q. EEG demonstrated unusual activities including diffuse fast activity, along with repetitive trains of paroxysmal fast activity during sleep. The most effective antiseizure drugs were oxcarbazepine for focal (9/11, 81%) and for generalized (2/3, 67%) epilepsy and valproic acid (6/10, 60%) for generalized epilepsy, whereas vigabatrin, zonisamide, and brivaracetam showed limited efficacy. In LGS, oxcarbazepine (8/12, 66%), valproic acid (11/18, 61%), and cannabidiol (6/9, 66%) yielded the best responses. All patients had early developmental delay; autism spectrum disorder was diagnosed in 22 of 54 (41%) and behavioral disorders in 30 of 54 (56%). Significance: Epilepsy in invdup15 is highly drug‐resistant and exhibits features consistent with DEEs, particularly LGS. EEG findings may serve as disorder biomarkers. Oxcarbazepine and valproic acid were the treatments most often associated with seizure improvement in this sample.

  • Open Access

    “Transcriptomic Profiling Unveils Novel Therapeutic Options for Drug-Resistant Temporal Lobe Epilepsy”

    by Patricia Sánchez-Jiménez, Lola Alonso-Guirado, Laura Cerrada-Gálvez, Marcos Elizalde-Horcada, Inmaculada Granero-Cremades, Paolo Maietta, Antonio Gómez-Martín, Francisco Abad-Santos, Cristina Virginia Torres-Díaz, Maria de Toledo, et al.

    Background: Epilepsy drug treatments fail in 25-30% of patients, who then develop drug resistance. Temporal lobe epilepsy is the most prevalent subtype associated with drug resistance. Classical drug discovery is a long and extremely costly process with a high rate of failure in clinical trials. Drug repurposing is a more cost- and time-effective strategy. Hence, the main objective of this study is to propose drug candidates for the treatment of drug-resistant temporal lobe epilepsy (DR-TLE) through drug repurposing based on transcriptomic profiling. Methods: Total RNA-sequencing (RNA-Seq) was performed on 45 formalin-fixed paraffin-embedded (FFPE) hippocampi of DR-TLE patients and 36 FFPE hippocampi of post-mortem biobank donors. RNA-Seq was carried out in an Illumina NovaSeq 6000 platform in 100bp paired-end. Drug repurposing based on transcriptomic analysis top candidates was performed against these databases: Pandrugs2, PharmOmics, DGIdb, ToppGene, L1000CDS 2 and Connectivity Map. Results: We found 887 genes differentially expressed between DR-TLE patients and post-mortem controls. We observed 74 potential drug candidates in at least two independent databases. Of these, we selected only the 11 which can cross the blood-brain barrier: cobimetinib, panobinostat, melphalan, rucaparib, alectinib, ponatinib, danazol, carboplatin, vandetanib, erlotinib, and gefitinib. After analyzing their safety and efficacy profile based on previous publications, we provide a list of the top 5 candidates. Conclusions: We therefore propose erlotinib, danazol, rucaparib, ponatinib, and panobinostat as potential therapies for DR-TLE based on differential RNA-Seq profiling.


  • Open Access

    Neuronal and astrocytic tetraploidy is increased in drug‐resistant epilepsy

    by Ancor Sanz‐García, Patricia Sánchez‐Jiménez, Inmaculada Granero‐Cremades, María de Toledo, Paloma Pulido, Marta Navas, José María Frade, Matilde Desirée Pereboom‐Maicas, Cristina Virginia Torres‐Díaz, María C. Ovejero‐Benito

    Aims: Epilepsy is one of the most prevalent neurological diseases. A third of patients with epilepsy remain drug‐resistant. The exact aetiology of drug‐resistant epilepsy (DRE) is still unknown. Neuronal tetraploidy has been associated with neuropathology. The aim of this study was to assess the presence of tetraploid neurons and astrocytes in DRE.Methods: For that purpose, cortex, hippocampus and amygdala samples were obtained from patients subjected to surgical resection of the epileptogenic zone. Post‐mortem brain tissue of subjects without previous records of neurological, neurodegenerative or psychiatric diseases was used as control.Results: The percentage of tetraploid cells was measured by immunostaining of neurons (NeuN) or astrocytes (S100β) followed by flow cytometry analysis. The results were confirmed by image cytometry (ImageStream X Amnis System Cytometer) and with an alternative astrocyte biomarker (NDRG2). Statistical comparison was performed using univariate tests. A total of 22 patients and 10 controls were included. Tetraploid neurons and astrocytes were found both in healthy individuals and DRE patients in the three brain areas analysed: cortex, hippocampus and amygdala. DRE patients presented a higher number of tetraploid neurons (p = 0.020) and astrocytes (p = 0.002) in the hippocampus than controls. These results were validated by image cytometry.Conclusions: We demonstrated the presence of both tetraploid neurons and astrocytes in healthy subjects as well as increased levels of both cell populations in DRE patients. Herein, we describe for the first time the presence of tetraploid astrocytes in healthy subjects. Furthermore, these results provide new insights into epilepsy, opening new avenues for future treatment.


  • Open Access

    METHYLATION BIOMARKERS ASSOCIATED WITH DRUG-RESISTANT EPILEPSY

    by Patricia Sánchez Jiménez, Marcos Elizalde-Horcada, Ancor Sanz-García, Inmaculada Granero-Cremades, María De Toledo, Paloma Pulido, Marta Navas, Ana Beatriz Gago-Veiga, Lola Alonso-Guirado, María Concepción Alonso-Cerezo, et al.

    Epilepsy is a disabling neurological disease that affects 2% of the population. Drug-resistant epilepsy (DRE) affects 25-30% of epilepsy patients. Understanding its underlying mechanisms is key to adequately manage this condition. To analyze the main epigenetic marks of DRE an epigenome-wide association study was carried out including samples from different regions of DRE patients’ brain and peripheral blood. An Illumina Infinium MethylationEPIC BeadChip array including cortex, hippocampus, amygdala, and peripheral blood from DRE subjected to neurosurgical resection of the epileptogenic zone was used. Overall, 32, 59, 3210, and 6 differentially methylated probes (DMPs) associated with DRE were found in the hippocampus, amygdala, cortex, and peripheral blood, respectively. These DMPs harbored 19, 28, 1574, and 7 genes, respectively, which play different roles in processes such as neurotrophic or calcium signaling. Three of the top DMPs observed in cortex were validated with methylation specific qPCR. Moreover, 163 DMPs associated with neurosurgery response at 6 months were found in the hippocampus. Genes located on these DMPs were involved in diverse processes such as synaptic signaling and central nervous system development. Besides 3 DMPs in blood samples were associated with response to neurosurgery at 12 months. In conclusion, the present study reports genome-wide DNA methylation changes across different regions of the DRE brain. These changes could be useful for further studies to disentangle the bases of DRE to search for therapeutic alternatives for this disease. Furthermore, they could also help identify patients likely to respond to neurosurgery.

  • Predictors of perfusion computed tomography alterations in stroke mimics attended as stroke code

    by Alicia Gonzalez‐Martinez, Santiago Trillo, Carmen Benavides‐Bernaldo de Quirós, Laura Casado‐Fernández, María De Toledo, Antonio Barbosa‐Del Olmo, Lorena Vega Piris, Carmen Ramos, Rafael Manzanares‐Soler, Álvaro Ximénez‐Carrillo, et al.

    Background and purpose: Stroke mimics (SMs) account for a significant number of patients attended as stroke code (SC) with an increasing number over the years. Recent studies show perfusion computed tomography (PCT) alterations in some SMs, especially in seizures. The objective of our study was to evaluate the clinical characteristics and PCT alterations in SMs attended as SC in order to identify potential predictors of PCT alterations in SMs.Methods: A retrospective study was performed including all SC activations undergoing a multimodal CT study including non‐enhanced computed tomography (CT), CT angiography and PCT, as part of our SC protocol, over 39 months. Patients with a final diagnosis of SM after complete diagnosis work‐up were therefore selected. Clinical variables, diagnosis, PCT alteration patterns and type of map affected (Tmax or time to peak, cerebral blood flow and cerebral blood volume) were registered.Results: Stroke mimics represent up to 16% (284/1761) of SCs with a complete multimodal study according to our series. Amongst SMs, 26% (74/284) showed PCT alterations. PCT abnormalities are more prevalent in seizures and status epilepticus and the main pattern is alteration of the time to peak map, of unilateral hemispheric distribution or of non‐vascular territory. In our series, the independent predictors of alteration in PCT in SMs are aphasia, female sex and older age.Conclusions: Perfusion computed tomography alterations can be found amongst almost a third of SMs attended as SC, especially older women presenting with aphasia with a final diagnosis of epileptic seizures and status epilepticus.


  • Open Access

    Utilidad de la tomografía computarizada cerebral multiparamétrica en el diagnóstico diferencial de patología comicial en el código ictus. Estudio preliminar

    by R. López Ruiz, S. Quintas, P. Largo, M. de Toledo, M.T. Carreras, A. Gago-Veiga, R. Manzanares, J. Vivancos


  • When aphasia is due to aphasic status epilepticus: a diagnostic challenge

    by Sonia Quintas, Juan Camilo Ródriguez-Carrillo, Rafael Toledano, María de Toledo, Francisco José Navacerrada Barrero, M. Álvaro Berbís, Ana Beatriz Gago-Veiga

    Aphasic status epilepticus is an uncommon entity that should be included in the differential diagnosis of persistent and sudden language disorders. In our study, we describe seven patients admitted with clinical and electroencephalographic diagnosis of aphasic status, who were studied with both neuroimaging and electroencephalogram. The mean age was 65.9 years (range of 39–89). Three of the patients had previously been diagnosed of epilepsy. The aphasia was global in six patients. In one case, we found foci of the left hemorrhagic contusions. The initial electroencephalogram (EEG) was not conclusive of status in two patients. In one patient, neuroimaging showed left hemispheric hypoperfusion, compatible with postictal changes. Six out of seven patients required at least two antiepileptic drugs. Three patients died of systemic complications (infectious causes), whereas the other four cases had a complete recovery. Our study highlights that a second EEG study might be necessary to confirm epileptiform activity, when clinical features and other tests suggest an epileptic origin. An early and specific treatment, avoiding or diminishing comorbidities, might significantly improve the prognosis of these patients.


  • Do people with epilepsy have a different lifestyle?

    by Clara Aguirre, Sonia Quintas, Ana María Ruiz-Tornero, Guadalupe Alemán, Ana Betariz Gago-Veiga, María de Toledo, Jose Vivancos


  • One‐year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability

    by Iñigo Garamendi‐Ruiz, María Eugenia García‐García, Vicente Bertol‐Alegre, José Ángel Mauri‐Llerda, Irene García‐Morales, Vanesa Garayoa‐Irigoyen, Marta Agúndez‐Sarasola, María De Toledo‐Heras, Vanessa García‐Morales, María José García‐Gomara, et al.

    Perampanel, a non‐competitive antagonist of the α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptors, is the most recent antiepileptic drug available in Spain, marketed in January 2014. It was initially approved by the European Medicines Agency as adjunctive treatment for partial‐onset seizures in patients 12 years and older, but recently also for primary generalized tonic‐clonic seizures. Although clinical trials provide essential information about the drug, they do not reflect daily clinical practice. This retrospective study shows the initial experience with perampanel in 11 Spanish hospitals during its first year post‐commercialisation. All patients who started perampanel treatment were included, but efficacy and tolerability were only assessed in those patients with a minimum follow‐up period of six months. In total, 256 patients were treated with perampanel before September 2014, and 253 had an observational period of one year. After six months, 216/256 patients (84%) continued on perampanel and 180/253 (71.1%) completed one year of treatment. The mean number of previous antiepileptic drugs used was 6.83 and the median number of concomitant antiepileptic drugs was 2. The mean perampanel dose was 7.06 mg and 8.26 mg at six and 12 months, respectively. The responder rate was 39.5% and 35.9% at both follow‐up points, respectively. Adverse events were experienced by 91/253 (35.5%) and resulted in withdrawal in 37 (14.6%). The most common adverse events were somnolence, dizziness, and irritability. We found no significant differences between concomitant use of enzyme‐inducing and non‐inducing antiepileptic drugs, regarding efficacy, adverse effects, or withdrawals. Irritability was not influenced by concomitant use of levetiracetam, relative to other drugs, but was more frequently observed in patients with a history of psychiatric problems or learning disabilities.


  • Familial benign frontotemporal deterioration with C9ORF72 hexanucleotide expansion

    by Estrella Gómez‐Tortosa, Soledad Serrano, María de Toledo, Julián Pérez‐Pérez, M. José Sainz

    Background: In recent years, a benign variant of frontotemporal lobar degeneration (FTLD) has been recognized, with a particularly slow progression of cognitive deficits and scarce frontotemporal atrophy or hypoperfusion in neuroimaging studies. Patients with FTLD have been considered “phenocopies,” with an underlying nondegenerative neurologic process.Results: We report the first family with three affected members having benign FTLD associated with C9ORF72 gene hexanucleotide expansion. Onset of symptoms occurred during the fifth decade, with naming and memory problems as the main features. Two siblings have stabilized at mild cognitive impairment or incipient dementia for more than a decade, and remain quite independent for their activities of daily living at the current ages of 69 and 65 years, respectively. Their mother's cognitive deterioration evolved slowly during >30 years.Conclusion: This family demonstrates that a benign evolution can be part of the growing spectrum of clinical phenotypes associated with neurodegenerative diseases caused by the C9ORF72 hexanucleotide expansion. Screening of this genetic marker should be considered in cases with this slow deterioration, especially if there is a family history.